← Gesamte Rechtsvorschrift

Art. 3 ·

EU-Recht · · Quelle: EUR-Lex · In Kraft

In EUR-Lex öffnen
Schriftgröße: 100 %

Article 3

For the infringements referred to in Article 1, the following fines are imposed on the following undertakings:

(a) F. Hoffmann-La Roche AG:

- a fine of EUR 85,5 million for its infringement in the vitamin A market,

- a fine of EUR 99,75 million for its infringement in the vitamin E market,

- a fine of EUR 42 million for its infringement in the vitamin B2 market,

- a fine of EUR 54 million for its infringement in the vitamin B5 market,

- a fine of EUR 65,25 million for its infringement in the vitamin C market,

- a fine of EUR 21 million for its infringement in the vitamin D3 market,

- a fine of EUR 48 million for its infringement in the beta-carotene market,

- a fine of EUR 46,5 million for its infringement in the carotinoids market,

(b) BASF AG:

- a fine of EUR 46,17 million for its infringement in the vitamin A market,

- a fine of EUR 89,78 million for its infringement in the vitamin E market,

- a fine of EUR 18,9 million for its infringement in the vitamin B2 market,

- a fine of EUR 34,02 million for its infringement in the vitamin B5 market,

- a fine of EUR 14,68 million for its infringement in the vitamin C market,

- a fine of EUR 7,56 million for its infringement in the vitamin D3 market,

- a fine of EUR 43,2 million for its infringement in the beta-carotene market,

- a fine of EUR 41,85 million for its infringement in the carotinoids market,

(c) Aventis SA: a fine of EUR 5,04 million for its infringement in the vitamin D3 market;

(d) Takeda Chemical Industries Ltd:

- a fine of EUR 8,78 million for its infringement in the vitamin B2 market,

- a fine of EUR 28,28 million for its infringement in the vitamin C market;

(e) Merck KgaA: a fine of EUR 9,24 million for its infringement in the vitamin C market;

(f) Daiichi Pharmaceutical Co. Ltd: a fine of EUR 23,4 million for its infringement in the vitamin B5 market;

(g) Solvay Pharmaceuticals BV: a fine of EUR 9,1 million for its infringement in the vitamin D3 market;

(h) Eisai Co. Ltd: a fine of EUR 13,23 million for its infringement in the vitamin E market.